TTF-1及TS在肺腺癌中的表达及与培美曲塞化疗疗效相关性分析
Relationship between Expression of TTF-1, TS and Chemotherapy Effect of Pemetrexed in Advanced Lung Adenocarcinoma
DOI: 10.12677/WJCR.2018.81004, PDF,    科研立项经费支持
作者: 朱林佳, 上官宗校, 慈 晓, 原少斐*, 赵仁国:温州医科大学附属第三医院呼吸内科,浙江 温州
关键词: 肺腺癌培美曲塞甲状腺转录因子-1胸苷酸合成酶Advanced Lung Adenocarcinoma Pemetrexed TTF-1 TS
摘要: 目的:探讨晚期肺腺癌中TTF-1和TS的表达与培美曲塞化疗疗效的关系。方法:回顾性分析80例接受培美曲塞化疗的晚期肺腺癌患者的临床病理资料。免疫组织化学法检测肿瘤标本TTF-1和TS蛋白的表达,并对疗效进行分析。结果:TTF-1阳性表达率为71.25% (57/80),TS阳性表达率为22.50% (18/80)。TTF-1和TS在肺癌中的表达呈负相关性(r = −0.356,P = 0.002)。化疗有效率(CR + PR)为46.25%,TTF-1(+)患者有效率(64.91%)显著高于TTF-1(−)患者(39.13%),差异有显著性(P < 0.05)。TS(+)患者有效率(27.78%)显著低于TS(−)患者51.61%,差异有显著性(P < 0.05)。联合检测显示:TTF-1(−)且TS(+)组有效率为28.57%,中位无疾病进展时间为3.9个月,1年生存率为28.6%,TTF-1(+)且TS(−)组有效率为81.13%,中位无疾病进展时间为7.4个月,1年生存率为69.8%,差异均有显著性(P < 0.05)。结论: 联合检测TTF-1和TS的表达可作为培美曲塞化疗方案治疗晚期肺腺癌的疗效预测指标之一。
Abstract: Objective: To investigate the relationship between expression of TTF-1, TS and chemotherapy effect of pemetrexed in advanced lung adenocarcinoma. Methods: Eighty patients with advanced lung adenocarcinoma treating by pemetrexed were enrolled in this study and their tumor samples were collected retrospectively for analysis. The expression of TTF-1, TS protein in tumor samples was de-tected by the immunohistochemical method. The data of therapeutical effect and toxicity were col-lected and analyzed. Results: The TTF-1 positive staining accounted for 71.25% (57/80). The TS positive staining accounted for 22.50% (18/80). TTF-1 and TS expression in lung cancer tissues had negative correlation (r = −0.356, P = 0.002). The response rate (CR + PR) was 46.25%. The efficiency of patients with over-expression of TTF-1 (64.91%) was significant higher than patients with low-expression of TTF-1 (39.13%) (P < 0.05). The efficiency of patients with over-expression of TS (27.78%) was significant lower than patients with low-expression of TS (51.61%) (P < 0.05). The ef-ficiency, median progress time and 1-survival rate of patients with over-expression TS and low-expression of TTF-1 (28.57%, 3.9 months, 28.6%) were all significant lower than patients with over-expression TTF-1 and low-expression of TS (81.13%, 7.4 months, 69.8%) (P < 0.05). Conclu-sions: The expression of TTF-1 and TS is associated with chemotherapy effect of pemetrexed in ad-vanced lung adenocarcinoma and can be used to detect the sensitivity.
文章引用:朱林佳, 上官宗校, 慈晓, 原少斐, 赵仁国. TTF-1及TS在肺腺癌中的表达及与培美曲塞化疗疗效相关性分析[J]. 世界肿瘤研究, 2018, 8(1): 18-25. https://doi.org/10.12677/WJCR.2018.81004

参考文献

[1] Tomasini, P., Barlesi, F., Mascaux, C., et al. (2016) Pemetrexed for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: Latest Evidence about Its Extended Use and Outcomes. Therapeutic Advances in Medical Oncology, 8, 198-208. [Google Scholar] [CrossRef] [PubMed]
[2] Liu, D., Wu, J., Shi, G.Y. (2014) Role of XRCC1 and ERCC5 Polymorphisms on Clinical Outcomes in Advanced Non-Small Cell Lung Cancer. Genetics and Molecular Research, 13, 3100-3107. [Google Scholar] [CrossRef
[3] Yaman, B., Nart, D., Ekren, P.K., et al. (2015) Expression of p63, TTF-1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis. Turkish Journal of Pathology, 31, 163-174. [Google Scholar] [CrossRef] [PubMed]
[4] Dong, H., Bao, D., Guo, X., et al. (2015) Effect of Thymidylate Synthase Gene Polymorphism on the Response to Chemotherapy and Clinical Outcome of Non-Small Cell Lung Cancer Patients. Tumor Biology, 36, 7151-7157. [Google Scholar] [CrossRef] [PubMed]
[5] Sun, J.M., Ahn, J.S., Jung, S.H., et al. (2015) Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Bio-marker-Stratified Randomized Phase II Trial. Journal of Clinical Oncology, 33, 2450-2456. [Google Scholar] [CrossRef
[6] 李燕, 杨明珍. 弥漫大B细胞淋巴瘤免疫组化标记的预后意义及利妥昔单抗对其影响临床研究[J]. 中国实用内科杂志, 2014, 34(2): 187-190.
[7] Tian, D., Pei, Y., Zheng, Q., et al. (2017) Effect of Vis-ceral Pleural Invasion on the Prognosis of Patients with Lymph Node Negative Non-Small Cell Lung Cancer. Thoracic Cancer, 8, 97-105. [Google Scholar] [CrossRef] [PubMed]
[8] Elsamany, S.A., Al-Fayea, T.M., Alzahrani, A.S., et al. (2015) Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome. Asian Pacific Organization for Cancer Prevetion, 16, 2987-2991. [Google Scholar] [CrossRef
[9] El-Maqsoud, N.M., Tawfiek, E.R., Abdelmeged, A., et al. (2016) The Diagnostic Utility of the Triple Markers Napsin A, TTF-1, and PAX8 in Differentiating between Primary and Metastatic Lung Carcinomas. Tumor Biology, 37, 3123-3134. [Google Scholar] [CrossRef] [PubMed]
[10] Winslow, M.M., Dayton, T.L., Verhaak, R.G., et al. (2013) Suppression of Lung Adenocarcinoma Progression by Nkx2-1. Nature, 473, 101-104. [Google Scholar] [CrossRef] [PubMed]
[11] Lee, J.S., Kim, H.R., Lee, C.Y., et al. (2013) EGFR and TTF-1 Gene Amplification in Surgically Resected Lung Adenocarcinomas: Clinicopathologic Significance and Effect on Response to EGFR-Tyrosine Kinase Inhibitors in Recurred Cases. Annals of Surgical Oncology, 20, 3015-3022. [Google Scholar] [CrossRef] [PubMed]
[12] Liu, Q., Yu, Z., Xiang, Y., Wu, N., et al. (2015) Prognostic and Predictive Significance of Thymidylate Synthase Protein Expression in Non-Small Celllung Cancer: A Systematic Review and Me-ta-Analysis. Cancer Biomarkers, 15, 65-78. [Google Scholar] [CrossRef
[13] Yang, M., Fan, W.F., Pu, X.L., et al. (2017) The Role of Thymidylate Synthase in Non-Small Cell Lung Cancer Treated with Pemetrexed Continuation Maintenance Therapy. Journal of Chemotherapy, 29, 106-112. [Google Scholar] [CrossRef
[14] Giovannetti, E., Zucali, P.A., Rolfo, C., et al. (2016) Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open. Journal of Clinical Oncology, 34, 511-512. [Google Scholar] [CrossRef